Shanghai, Nov. 3, 2022 – Regor Therapeutics, a clinical-stage biotech company, announced today the Investigational New Drug (IND) Application for RGT-264 phosphate tablet, a small molecular selective hematopoietic progenitor kinase (HPK1) inhibitor has been approved by the National Medical Products Administration (NMPA) of China.

RGT-264 phosphate tablet is a highly potent and selective HPK1 inhibitor. HPK1 kinase activity suppresses the immune functions of a wide range of cells including T cells and dendritic cells (DCs) 1. Therefore, inhibiting HPK1 activity serves as a promising approach for cancer immunotherapy. Currently, there is no HPK1 inhibitor approved globally.

The phase 1 clinical trial is the first-in-human (FIH) study of RGT-264 phosphate tablet, aims to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary anti-tumor activity of RGT-264 as the monotherapy in subjects with advanced solid tumors.

About Regor Therapeutics Group

Regor Therapeutics is a clinical stage company dedicated to the discovery and development of innovative and clinically differentiated medicines by leveraging the proprietary rCARD^TM platform. The company focuses mainly on three therapeutic areas, oncology, immunology, and metabolic disorders. By seamlessly integrating rCARD^TM with structural biology, computational chemistry, biology, medicinal chemistry, and clinical development, Regor has successfully assembled a world-class scientific team and established a highly efficient new drug innovation engine to enable the discovery and development of best- and first-in-class molecules.

Reference

1. Wang X, Li JP, Chiu LL, et al. Attenuation of T cell receptor signaling by serine phosphorylation-mediated lysine 30 ubiquitination of SLP-76 protein. J Biol Chem. 2012;287(41):34091-34100. doi:10.1074/jbc.M112.371062

IR Contact:

  Investor Relations and Communications

  Email: ir@regor.com